Similar articles for PMID: 35074846

Year	Number of Results
2007	1
2010	3
2011	4
2012	3
2013	3
2014	8
2015	6
2016	14
2017	16
2018	15
2019	16
2020	7
2021	10
2022	3

1

How I Treat Complement-Mediated TMA.

Sperati CJ. Sperati CJ. Clin J Am Soc Nephrol. 2022 Mar;17(3):452-454. doi: 10.2215/CJN.13581021. Epub 2022 Jan 24. Clin J Am Soc Nephrol. 2022. PMID: 35074846 No abstract available.

2

Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.

Ito S, Hidaka Y, Inoue N, Kaname S, Kato H, Matsumoto M, Miyakawa Y, Mizuno M, Okada H, Shimono A, Matsuda T, Maruyama S, Fujimura Y, Nangaku M, Kagami S. Ito S, et al. Clin Exp Nephrol. 2019 Jan;23(1):112-121. doi: 10.1007/s10157-018-1610-2. Epub 2018 Jul 23. Clin Exp Nephrol. 2019. PMID: 30039480 Free PMC article.

3

A rare case of Alport syndrome, atypical hemolytic uremic syndrome and Pauci-immune crescentic glomerulonephritis.

Tao J, Lieberman J, Lafayette RA, Kambham N. Tao J, et al. BMC Nephrol. 2018 Dec 12;19(1):355. doi: 10.1186/s12882-018-1170-4. BMC Nephrol. 2018. PMID: 30541482 Free PMC article.

4

Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.

Kato H, Miyakawa Y, Hidaka Y, Inoue N, Ito S, Kagami S, Kaname S, Matsumoto M, Mizuno M, Matsuda T, Shimono A, Maruyama S, Fujimura Y, Nangaku M, Okada H. Kato H, et al. Clin Exp Nephrol. 2019 Jan;23(1):65-75. doi: 10.1007/s10157-018-1609-8. Epub 2018 Jun 29. Clin Exp Nephrol. 2019. PMID: 29959568 Free PMC article.

5

Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.

Fakhouri F, Fila M, Provôt F, Delmas Y, Barbet C, Châtelet V, Rafat C, Cailliez M, Hogan J, Servais A, Karras A, Makdassi R, Louillet F, Coindre JP, Rondeau E, Loirat C, Frémeaux-Bacchi V. Fakhouri F, et al. Clin J Am Soc Nephrol. 2017 Jan 6;12(1):50-59. doi: 10.2215/CJN.06440616. Epub 2016 Oct 31. Clin J Am Soc Nephrol. 2017. PMID: 27799617 Free PMC article.

6

Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation.

Ueda Y, Miwa T, Ito D, Kim H, Sato S, Gullipalli D, Zhou L, Golla M, Song D, Dunaief JL, Palmer MB, Song WC. Ueda Y, et al. Kidney Int. 2019 Jul;96(1):67-79. doi: 10.1016/j.kint.2019.01.009. Epub 2019 Feb 27. Kidney Int. 2019. PMID: 30910380

7

Secondary atypical hemolytic uremic syndromes in the era of complement blockade.

Praga M, Rodríguez de Córdoba S. Praga M, et al. Kidney Int. 2019 Jun;95(6):1298-1300. doi: 10.1016/j.kint.2019.01.043. Kidney Int. 2019. PMID: 31122707

8

Thrombotic microangiopathy: focus on atypical hemolytic uremic syndrome.

Sperati CJ, Moliterno AR. Sperati CJ, et al. Hematol Oncol Clin North Am. 2015 Jun;29(3):541-59. doi: 10.1016/j.hoc.2015.02.002. Epub 2015 Apr 4. Hematol Oncol Clin North Am. 2015. PMID: 26043391 Review.

9

Does severe ADAMTS13 deficiency in thrombotic microangiopathy rule out complement-mediated atypical hemolytic uremic syndrome.

Arumugam V, Bhowmick R, Agarwal I, Arumadi M. Arumugam V, et al. Saudi J Kidney Dis Transpl. 2019 May-Jun;30(3):701-705. doi: 10.4103/1319-2442.261349. Saudi J Kidney Dis Transpl. 2019. PMID: 31249236 Free article.

10

Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015.

Noris M, Remuzzi G. Noris M, et al. Am J Kidney Dis. 2015 Aug;66(2):359-75. doi: 10.1053/j.ajkd.2015.03.040. Epub 2015 May 29. Am J Kidney Dis. 2015. PMID: 26032627 Free PMC article. Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed